EMA To Advise On Tweaking COVID-19 Vaccines Due To New Variants
Concerns that new or future mutations of the novel coronavirus may reduce the protection offered by existing COVID-19 vaccines have prompted the European Medicines Agency to develop guidance to help vaccine manufacturers who are planning to alter to their products.
You may also be interested in...
Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.
Close monitoring of the effectiveness of coronavirus vaccines will be necessary after a new variant of SARS-CoV-2 was reported to be causing a rapid increase in transmission of the virus in the UK. The pharmaceutical industry says companies are not expecting travel restrictions imposed on the UK to have an impact on the supply of medicines.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.